Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

D-methyldopa - IM Therapeutics

X
Drug Profile

D-methyldopa - IM Therapeutics

Alternative Names: IMT-002

Latest Information Update: 28 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Colorado at Denver
  • Developer IM Therapeutics
  • Class Amines; Antihyperglycaemics; Catechols; Propionic acids; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor agonists; HLA-DQ8 antigen inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Type 1 diabetes mellitus
  • New Molecular Entity No

Highest Development Phases

  • No development reported Coeliac disease; Type 1 diabetes mellitus

Most Recent Events

  • 28 Jul 2023 No recent reports of development identified for phase-I development in Type-1 diabetes mellitus in USA (PO)
  • 28 Dec 2021 No recent reports of development identified for preclinical development in Coeliac disease in USA (PO)
  • 22 Jul 2021 Safety, pharmacokinetics and pharmacodynamics data from phase Ib trial in Type 1 diabetes mellitus released by IM Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top